Literature DB >> 23430509

Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.

Hiroaki Itamochi1, Misaki Kato, Mayumi Nishimura, Nao Oumi, Tetsuro Oishi, Muneaki Shimada, Shinya Sato, Jun Naniwa, Seiya Sato, Michiko Nonaka, Akiko Kudoh, Naoki Terakawa, Junzo Kigawa, Tasuku Harada.   

Abstract

A new cell line of human ovarian clear cell adenocarcinoma (CCC), TU-OC-1, was established and characterized. The cells showed a polygonal-shaped morphology and grew in monolayers without contact inhibition and were arranged like a jigsaw puzzle. The chromosome numbers ranged from 64 to 90. A low rate of proliferation was observed, similar to other CCC cell lines tested (OVTOKO, RMG-I, and OVAS), and the doubling time was 38.4 h. The respective IC50 values of cisplatin and paclitaxel were 12.2 μM and 58.3 nM. Mutational analysis revealed that TU-OC-1 cells harbored a PIK3CA mutation at codon 542 (E542K) in exon 9, which is a mutation hot spot on this gene. We observed that phosphorylated Akt protein was overexpressed in TU-OC-1 cells by western blot analysis. Heterotransplantation to nude mice produced tumors that reflected the original. This cell line may be useful to study the chemoresistant mechanisms of CCC and contribute to novel treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23430509     DOI: 10.1007/s13577-013-0062-y

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  26 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Inhibition of the PI3K pathway: hope we can believe in?

Authors:  Michiel S van der Heijden; René Bernards
Journal:  Clin Cancer Res       Date:  2010-04-16       Impact factor: 12.531

3.  Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.

Authors:  Melissa K McConechy; Michael S Anglesio; Steve E Kalloger; Winnie Yang; Janine Senz; Christine Chow; Alireza Heravi-Moussavi; Gregg B Morin; Anne-Marie Mes-Masson; Mark S Carey; Jessica N McAlpine; Janice S Kwon; Leah M Prentice; Niki Boyd; Sohrab P Shah; C Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2011-03-07       Impact factor: 7.996

Review 4.  The PI3K-PDK1 connection: more than just a road to PKB.

Authors:  B Vanhaesebroeck; D R Alessi
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

5.  Somatic mutations of PPP2R1A in ovarian and uterine carcinomas.

Authors:  Ie-Ming Shih; Pradeep K Panuganti; Kuan-Tin Kuo; Tsui-Lien Mao; Elisabetta Kuhn; Sian Jones; Victor E Velculescu; Robert J Kurman; Tian-Li Wang
Journal:  Am J Pathol       Date:  2011-02-26       Impact factor: 4.307

Review 6.  Ovarian cancer: strategies for overcoming resistance to chemotherapy.

Authors:  Roshan Agarwal; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

Review 7.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

8.  Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells.

Authors:  M H Barcellos-Hoff; L J Marton; D F Deen
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

9.  Mutations of PIK3CA in gastric adenocarcinoma.

Authors:  Vivian Sze Wing Li; Chi Wai Wong; Tsun Leung Chan; Agnes Sze Wah Chan; Wei Zhao; Kent-Man Chu; Samuel So; Xin Chen; Siu Tsan Yuen; Suet Yi Leung
Journal:  BMC Cancer       Date:  2005-03-23       Impact factor: 4.430

10.  Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

Authors:  M Takano; Y Kikuchi; N Yaegashi; K Kuzuya; M Ueki; H Tsuda; M Suzuki; J Kigawa; S Takeuchi; H Tsuda; T Moriya; T Sugiyama
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

View more
  7 in total

1.  Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.

Authors:  Seiya Sato; Hiroaki Itamochi; Nao Oumi; Youhei Chiba; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Chikumi; Michiko Nonaka; Akiko Kudoh; Hiroaki Komatsu; Tasuku Harada; Toru Sugiyama
Journal:  Hum Cell       Date:  2016-03-09       Impact factor: 4.174

2.  Exosomal MicroRNA as Biomarkers for Diagnosing or Monitoring the Progression of Ovarian Clear Cell Carcinoma: A Pilot Study.

Authors:  Kayo Horie; Naoki Nanashima; Yoshihito Yokoyama; Haruhiko Yoshioka; Jun Watanabe
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

3.  Establishment and characterization of a clear cell carcinoma cell line, designated NOCC, derived from human ovary.

Authors:  Akihiro Ohyama; Junko Toyomura; Toshiaki Tachibana; Seiji Isonishi; Haruka Takahashi; Hiroshi Ishikawa
Journal:  Hum Cell       Date:  2016-08-19       Impact factor: 4.174

4.  GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer.

Authors:  H Yagi; K Asanoma; T Ohgami; A Ichinoe; K Sonoda; K Kato
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

5.  Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).

Authors:  Wei Jiang; Shuang Ye; Libing Xiang; Wentao Yang; Tiancong He; Xuan Pei; Lin Guo; Huijuan Yang
Journal:  J Ovarian Res       Date:  2018-07-09       Impact factor: 4.234

6.  Establishment and characterization of a cell line (HCH-1) originating from a human clear cell carcinoma of the ovary.

Authors:  Takashi Yamada; Kimiaki Hattori; Hidetoshi Satomi; Tadashi Okazaki; Hiroshi Mori; Yoshinobu Hirose
Journal:  J Ovarian Res       Date:  2016-06-04       Impact factor: 4.234

7.  Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.

Authors:  Miriam Franklin; Lucy Gentles; Elizabeth Matheson; Nick Bown; Paul Cross; Angela Ralte; Connor Gilkes-Immeson; Alice Bradbury; Maryam Zanjirband; John Lunec; Yvette Drew; Rachel O'Donnell; Nicola J Curtin
Journal:  Cancer Med       Date:  2018-08-14       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.